E. Balestre and M. Brinkhof, François Dabis (principal investigator) Matthias Egger (principal investigator)

I. , C. Inserm, and U. , 3 INSERM, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, F-33000 School of Public Health and Family Medicine, Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire (CHU)

M. Pujades-rodriguez, O. Brien, D. Humblet, P. Calmy, and A. , Second-line antiretroviral therapy in resource-limited settings: the experience of M??decins Sans Fronti??res, AIDS, vol.22, issue.11, pp.1305-1312, 2008.
DOI : 10.1097/QAD.0b013e3282fa75b9

O. Keiser, C. Orrell, M. Egger, H. Swiss, and . Study, Public-Health and Individual Approaches to Antiretroviral Therapy: Township South Africa and Switzerland Compared, PLoS Medicine, vol.368, issue.7, pp.148-195, 2008.
DOI : 10.1371/journal.pmed.0050148.sd001

O. Keiser, H. Tweya, A. Boulle, A. Of-iedea-study, and . Group, Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring, AIDS, vol.23, pp.1867-74, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00385651

F. Renaud-théry, B. Nguimfack, M. Vitoria, E. Lee, P. Graaff et al., Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first-and second-line regimens, AIDS, vol.4, pp.89-95, 2007.

. Unaids, Available from: http://www.unaids.org/en/ Dataanalysis, Epidemiology, 2009.

H. World and . Organization, Antiretroviral therapy for HIV Infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach Available from http, 2011.

D. Moore, J. Mermin, A. Awor, B. Yip, R. Hogg et al., Performance of Immunologic Responses in Predicting Viral Load Suppression, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.43, issue.4, pp.436-439, 2006.
DOI : 10.1097/01.qai.0000243105.80393.42

S. Koenig, D. Kuritzkes, and M. Hirsch, Monitoring HIV treatment in developing countries, BMJ, vol.332, issue.7541, pp.602-604, 2006.
DOI : 10.1136/bmj.332.7541.602

J. Mermin, J. Ekwaru, and W. Were, Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults in Uganda: A randomized trial, BMJ, 2011.

. Dart-trial-team, P. Mugyenyi, A. Walker, J. Hakim, P. Munderi et al., Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized non-inferiority trial, Lancet, vol.375, pp.123-154, 2010.

L. Chang, J. Harris, and E. Humphreys, Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HVI in lowresource settings, Cochrane Database Syst Rev, vol.4, p.8494, 2010.

G. Jourdain and N. Ngo-giang-huong, PHPT-3: a randomized clinical trial comparing CD4 vs. viral load ART monitoring/Switching strategies in Thailand.I n18th Conference on retroviruses and opportunistic infections, 2011.

C. Kouanfack, C. Laurent, G. Laborde-balen, /. Esther-study, and . Group, HIV viral load, CD4 cell count, and clinical monitoring s. clinical monitoring alone for ART in rural hospitals in Cameroon: stratall ANRS 12110, In18th Conference on retroviruses and opportunistic infections, 2011.

H. World and . Organization, Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach Available from http, 2010.

P. Collaboration, Predictors of trends in CD4-positive T cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes, Lancet, vol.364, pp.51-62, 2004.

R. Murri, A. Cozzi-perri, P. Cicconi, and . For-the-icona-study-group, Is Moderate HIV Viremia Associated With a Higher Risk of Clinical Progression in HIV-Infected People Treated With Highly Active Antiretroviral Therapy, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.41, issue.1, pp.23-30, 2006.
DOI : 10.1097/01.qai.0000188337.76164.7a

F. Dabis, E. Balestre, and P. Braitstein, Antiviral Therapy in Lower Income Countries (ART-LINC) Study Group. Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts, Int J Epidemiol, vol.34, pp.979-86, 2005.

J. Nachega, M. Hislop, and H. Nguyen, Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern Africa, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.51, issue.1, pp.65-71, 2009.
DOI : 10.1097/QAI.0b013e318199072e

A. Bourgeois, C. Laurent, and R. Mougnutou, Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon, Antivir Ther, vol.10, pp.335-376, 2005.

C. Lepri, A. Phillips, A. Monforte, and A. , When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study, AIDS, vol.15, issue.8, pp.983-90, 2001.
DOI : 10.1097/00002030-200105250-00006

A. Linc-collaboration and A. Collaboration, Mortality of HIV1-infected patients in the first year of antiretroviral therapy: comparison between lowincome and high-income countries, Lancet, vol.367, pp.817-824, 2006.

A. Redd, D. Dabitao, and J. Bream, Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa, Proceedings of the National Academy of Sciences, vol.106, issue.16, pp.6718-6741, 2009.
DOI : 10.1073/pnas.0901983106

A. Cozzi-lepri, A. Phillips, J. Martinez-picado, and E. Study-group, Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resource???Limited Settings, The Journal of Infectious Diseases, vol.200, issue.5, pp.687-97, 2009.
DOI : 10.1086/604731

C. Seyler, C. Adje-toure, and E. Messou, Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa, AIDS, vol.21, issue.9, pp.1157-1164, 2007.
DOI : 10.1097/QAD.0b013e3281c615da
URL : https://hal.archives-ouvertes.fr/inserm-00172158

A. Phillips, D. Pillay, and G. Garnett, Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings, AIDS, vol.25, issue.6, pp.843-850, 2011.
DOI : 10.1097/QAD.0b013e328344037a

M. Cohen, Y. Chen, and M. Mccauley, Prevention of HIV-1 Infection with Early Antiretroviral Therapy, New England Journal of Medicine, vol.365, issue.6, pp.493-505, 2011.
DOI : 10.1056/NEJMoa1105243

C. Hoffmann, S. Charalambous, and J. Sim, Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during First???Line Antiretroviral Therapy in South Africa, Clinical Infectious Diseases, vol.49, issue.12, pp.1928-1935, 2009.
DOI : 10.1086/648444

M. Petersen, M. Van-der-laan, and S. Napravnik, Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification, AIDS, vol.22, issue.16, pp.2097-2106, 2008.
DOI : 10.1097/QAD.0b013e32830f97e2

O. Keiser, H. Tweya, and P. Braitstein, Mortality after failure of antiretroviral therapy in sub-Saharan Africa, Tropical Medicine & International Health, vol.366, issue.2, pp.251-259, 2010.
DOI : 10.1111/j.1365-3156.2009.02445.x

X. Anglaret, A. Minga, and D. Gabillard, AIDS and Non-AIDS Morbidity and Mortality Across the Spectrum of CD4 Cell Counts in HIV-Infected Adults Before Starting Antiretroviral Therapy in Cote d'Ivoire, Clinical Infectious Diseases, vol.54, issue.5, pp.714-737, 2012.
DOI : 10.1093/cid/cir898